IP Library Granted Patent US 10,946,090
Granted Patent B2
US 10,946,090 · App. 15/813,992 · Granted Mar 16, 2021

Consensus/ancestral immunogens

Inventors: Barton F. Haynes (Durham, NC); Feng Gao (Durham, NC); Bette T. Korber (Los Alamos, NM); Beatrice H. Hahn (Birmingham, AL); George M. Shaw (Birmingham, AL); Denise L. Monti (Birmingham, AL); Ying Ying Li (Birmingham, AL); Julie Decker (Birmingham, AL); Hua-Xin Liao (Durham, NC)
Assignees: Duke University; The University of Alabama at Birmingham Research Foundation; Triad National Security, LLC
A61K39/21A61K39/12C07K14/005C07K16/4225A61K2039/53A61K2039/57C12N2740/15022C12N2740/15034C12N2740/16034C12N2740/16122C12N2740/16134C12N2740/16222C12N2740/16322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,946,090
App. No.
15/813,992
Granted
Mar 16, 2021
Kind
B2
Abstract

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Claims (18)

1. A nucleic acid comprising a nucleotide sequence that encodes a group M consensus Env comprising SEQ ID NO: 13, or a Cons-S gp140CFI Env comprising SEQ ID NO: 30, or a CON-S gp140CF Env comprising SEQ ID NO: 36.

2. The nucleic acid according to claim 1 , wherein said nucleotide sequence comprises codons optimized for expression in human cells.

3. The nucleic acid according to claim 2 , wherein said nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 14.

4. The nucleic acid according to claim 2 , wherein said nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 31.

5. The nucleic acid according to claim 2 , wherein said nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 37.

6. A nucleic acid comprising a nucleotide sequence that encodes a recombinant gp120 envelope protein, wherein the recombinant gp120 envelope protein comprises the consecutive amino acid sequence represented by amino acid numbers 30 to 503 of SEQ ID NO: 13.

7. The nucleic acid of claim 6 comprising the consecutive nucleotide sequence from SEQ ID NO: 14 that encodes the consecutive amino acid sequence represented by amino acid numbers 30 to 503 of SEQ ID NO: 13, wherein said nucleotide sequence comprises codons optimized for expression in human cells.

8. A vector comprising the nucleic acid according to claim 1 .

9. An isolated mammalian cell comprising a nucleic acid according to claim 1 for recombinant protein expression.

10. A vector comprising the nucleic acids of claim 6 .

11. A composition comprising the nucleic acid according to claim 1 and a carrier.

12. A method of inducing an immune response in a mammal, the method comprising administering to said mammal the composition of claim 11 in an amount sufficient to effect such induction.

13. A composition comprising the nucleic acid according to claim 1 and a carrier, wherein the nucleic acid comprises a nucleotide sequence that encodes a group M consensus Env comprising SEQ ID NO: 13 and a carrier.

14. A composition comprising the nucleic acid according to claim 6 and a carrier.

15. An isolated mammalian cell comprising the nucleic acid according to claim 1 , wherein the nucleic acid comprises a nucleotide sequence that encodes a group M consensus Env comprising SEQ ID NO: 13 or recombinant protein expression.

16. An isolated mammalian cell comprising the nucleic acid according to claim 6 for recombinant protein expression.

17. A method of inducing an immune response in a mammal, the method comprising administering to said mammal the composition of claim 13 in an amount sufficient to effect such induction.

18. A method of inducing an immune response in a mammal, the method comprising administering to said mammal the composition of claim 14 in an amount sufficient to effect such induction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: LOS ALAMOS NATIONAL SECURITY, LLC
To: TRIAD NATIONAL SECURITY, LLC
Reel/Frame 047485/0173 →